Sonoma Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 10, 2026
SNOA$1.14+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
FOR THE NINE MONTHS ENDED DECEMBER 31, 2025 AND 2024
(In thousands, except share amounts)
| Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Total | |
| Balance, March 31, 2025 | 1,634,265 | $– | $206,593 | $(197,806) | $(4,376) | $4,411 |
| Exercise of employee stock options | 8,500 | – | 23 | – | – | 23 |
| Employee stock-based compensation | – | – | 57 | – | – | 57 |
| Foreign currency translation adjustment | – | – | – | – | 806 | 806 |
| Net loss | – | – | – | (1,241) | – | (1,241) |
| Balance, June 30, 2025 | 1,642,765 | $– | $206,673 | $(199,047) | $(3,570) | $4,056 |
| Exercise of employee stock options | 7,000 | – | 21 | – | – | 21 |
| Employee stock-based compensation | – | – | 39 | – | – | 39 |
| Foreign currency translation adjustment | – | – | – | – | 205 | 205 |
| Net loss | – | – | – | (534) | – | (534) |
| Balance, September 30, 2025 | 1,649,765 | $– | $206,733 | $(199,581) | $(3,365) | $3,787 |
| Proceeds from At-the-Market sale of common stock, net of offering expenses | 80,848 | – | 266 | – | – | 266 |
| Employee stock-based compensation | – | – | 24 | – | – | 24 |
| Foreign currency translation adjustment | – | – | – | – | 174 | 174 |
| Net loss | – | – | – | (819) | – | (819) |
| Balance, December 31, 2025 | 1,730,613 | $– | $207,023 | $(200,400) | $(3,191) | $3,432 |
| Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Total | |
| Balance, March 31, 2024 | 780,371 | $– | $203,209 | $(194,349) | $(2,723) | $6,137 |
| Proceeds from At-the-Market sale of common stock, net of offering expenses | 158,311 | – | 748 | – | – | 748 |
| Exercise of employee stock options | 2,000 | – | 7 | – | – | 7 |
| Employee stock-based compensation | 9,538 | – | 107 | – | – | 107 |
| Foreign currency translation adjustment | – | – | – | – | (881) | (881) |
| Net loss | – | – | – | (1,143) | – | (1,143) |
| Balance, June 30, 2024 | 950,220 | $– | $204,071 | $(195,492) | $(3,604) | $4,975 |
| Proceeds from At-the-Market sale of common stock, net of offering expenses | 381,433 | – | 1,541 | – | – | 1,541 |
| Exercise of employee stock options | 7,250 | – | 26 | – | – | 26 |
| Payments for fractional shares related to reverse-split | (288) | – | (1) | – | – | (1) |
| Employee stock-based compensation | – | – | 14 | – | – | 14 |
| Foreign currency translation adjustment | – | – | – | – | (593) | (593) |
| Net loss | – | – | – | (610) | – | (610) |
| Balance, September 30, 2024 | 1,338,615 | $– | $205,651 | $(196,102) | $(4,197) | $5,352 |
| Proceeds from At-the-Market sale of common stock, net of offering expenses | 277,150 | – | 790 | – | – | 790 |
| Employee stock-based compensation | – | – | 13 | – | – | 13 |
| Foreign currency translation adjustment | – | – | – | – | (357) | (357) |
| Net loss | – | – | – | (928) | – | (928) |
| Balance, December 31, 2024 | 1,615,765 | $– | $206,454 | $(197,030) | $(4,554) | $4,870 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.